

## Supplementary Tables

Horpaopan et al.

Exome sequencing characterizes the somatic mutation spectrum of early serrated lesions in a patient with serrated polyposis syndrome (SPS)

**Supplementary Table S1** Established causative or candidate genes for (hereditary) colorectal tumours and published genes related to serrated polyps (n = 74)

No.	Gene	Chr	Disease / pathway / susceptibility	Ref.
1	<i>ACVR2</i>	2q22-23	Target gene in MMR-deficient CRC	[1]
2	<i>AHBD1</i>	2	Found LoF mutation in serrated polyposis families	[2]
3	<i>AIM2</i>	1q22	Target gene in MMR-deficient CRC	[1]
4	<i>APC</i>	5q22.2	Familial adenomatous polyposis (FAP)	[3]
5	<i>APC2</i>	19p13.3	Wnt signalling pathway, depletion of intracellular beta-catenin, specifically expressed in brain	[4]
6	<i>AXIN1</i>	16p13.3	Regulation of Wnt-beta-catenin signaling	[1]
7	<i>AXIN2</i>	17q24	Regulation of Wnt-beta-catenin signaling	[4, 5]
8	<i>BAX</i>	19q13.3	Target gene in MMR-deficient CRC	[1]
9	<i>BLM</i>	15q26.1	Target gene in MMR-deficient CRC	[1]
10	<i>BMPR1A</i>	10q22.3	Juvenile polyposis syndrome (JPS)	[4]
11	<i>BRAF</i>	7q34	Oncogene, somatic mutations in CRC	[6]
12	<i>BUB1B</i>	15q15	Gastrointestinal adenomas and carcinomas	[7]
13	<i>CA9</i>	9p13.3	Found LoF mutation in serrated polyposis families	[2]
14	<i>Caspase-5</i>	11q22.2	target gene in MMR-deficient CRC	[1]
15	<i>CASQ1</i>	1p3.2	Found LoF mutation in serrated polyposis families	[2]
16	<i>CDH1</i>	16q22.1	Hereditary diffuse gastric cancer (HDGC)	[8]
17	<i>CDX2</i>	13q12.3	target gene in MMR-deficient CRC	[1]
18	<i>CHEK2</i>	22q12.1	Susceptibility for CRC	[9, 10]
19	<i>CHK1</i>	11q22	Target gene in MMR-deficient CRC	[1]
20	<i>CNPY4</i>	7q22.1	Found LoF mutation in serrated polyposis families	[2]
21	<i>COL15A1</i>	9q22.3	Found LoF mutation in serrated polyposis families	[2]
22	<i>COL20A1</i>	20q13	Found LoF mutation in serrated polyposis families	[2]
23	<i>CREB3L3</i>	19p13	Found LoF mutation in serrated polyposis families	[2]
24	<i>CRYBA2</i>	2q35	Frequently overexpressed in <i>BRF</i> -mutant colon cancer	[11]
25	<i>CTNNB1</i>	3p21	canonical Wnt signaling pathway	[12]
26	<i>DDX31</i>	9q34	Found LoF mutation in serrated polyposis families	[2]
27	<i>E2F-4</i>	16q21	Target gene in MMR-deficient CRC	[1]
28	<i>EGFR</i>	7p12	Oncogene, somatic mutations in lung cancer	[13, 14]
29	<i>EMR2</i>	19p13	Found LoF mutation in serrated polyposis families	[2]
30	<i>ENDOG</i>	9q34.1	Found LoF mutation in serrated polyposis families	[2]
31	<i>EPCAM</i>	2p21	Lynch syndrome / HNPCC	[15]
32	<i>FAM123B</i>	Xq11.2	canonical Wnt signaling pathway	[16, 17]
33	<i>FBXW7</i>	4q31.3	Cyclin E degradation, frequently mutated in CRC	[4]
34	<i>FLI1</i>	11q24.3	Candidate serrated polyposis gene	[18]
35	<i>FSCN1</i>	7p22.1	Frequently overexpressed in <i>BRF</i> -mutant colon cancer	[11]
36	<i>FSIP2</i>	2q32.1	Found LoF mutation in serrated polyposis families	[2]

37	<i>GCA</i>	2q24.2	Found LoF mutation in serrated polyposis families	[2]
38	<i>GCSAM</i>	3q13.2	Found LoF mutation in serrated polyposis families	[2]
39	<i>GEM</i>	8q22	Found LoF mutation in serrated polyposis families	[2]
40	<i>GJA3</i>	13q12.11	Candidate serrated polyposis gene	[18]
41	<i>GPT</i>	8q24.3	Found LoF mutation in serrated polyposis families	[2]
42	<i>GREM1</i>	15q13.3	Hereditary mixed polyposis syndrome 1	[8]
43	<i>GRWD1</i>	19q13	Found LoF mutation in serrated polyposis families	[2]
44	<i>GSK3B</i>	3q13.3	Canonical Wnt signaling pathway	[5]
45	<i>H3F3B</i>	17q25	Found LoF mutation in serrated polyposis families	[2]
46	<i>HDAC2</i>	6q21	Candidate serrated polyposis gene	[19]
47	<i>HDHD3</i>	9q32	Candidate serrated polyposis gene	[18]
48	<i>hRAD50</i>	5q31	Target gene in MMR-deficient CRC	[1]
49	<i>IDO2</i>	8p11.21	Found LoF mutation in serrated polyposis families	[2]
50	<i>IGF2</i>	11p15.5	Candidate serrated polyposis gene	[19]
51	<i>IGFBP7</i>	4q12	Candidate serrated polyposis gene	[20]
52	<i>IGFIIR</i>	6q26-27	Target gene in MMR-deficient CRC	[1]
53	<i>IGSF6</i>	16p12.2	Found LoF mutation in serrated polyposis families	[2]
54	<i>IMPACT</i>	18q11	Found LoF mutation in serrated polyposis families	[2]
55	<i>KRAS</i>	12p12.1	Oncogene, frequently mutated in CRC	[6]
56	<i>MAP2K4</i>	17p12	MAPK pathway, mutated in CRC	[21, 22]
57	<i>MBD4</i>	3q21-q22	target gene in MMR-deficient CRC	[1]
58	<i>MGAT5B</i>	17q25	Found LoF mutation in serrated polyposis families	[2]
59	<i>MGMT</i>	10q26.3	Candidate serrated polyposis gene	[23]
60	<i>MLH1</i>	3p22.2	Candidate serrated polyposis gene	[20]
61	<i>MLH3</i>	14q24.3	Candidate serrated polyposis gene	[23]
62	<i>MSH2</i>	2p21	Candidate serrated polyposis gene	[23]
63	<i>MSH3</i>	5q11-q12	Target gene in MMR-deficient CRC	[1]
64	<i>MSH6</i>	2p16.3	Candidate serrated polyposis gene	[23]
65	<i>MUC6</i>	11p15	Frequently overexpressed in <i>BRF</i> -mutant colon cancer	[11]
66	<i>MUTYH</i>	1p32-34	<i>MUTYH</i> -associated polyposis (MAP)	[24]
67	<i>MYH15</i>	3q13.1	Found LoF mutation in serrated polyposis families	[2]
68	<i>NCAN</i>	19p13	Found LoF mutation in serrated polyposis families	[2]
69	<i>NRAS</i>	1p13.2	Noonan syndrome, rarely mutated in CRC	[25]
70	<i>OR4L1</i>	14q11	Found LoF mutation in serrated polyposis families	[2]
71	<i>PDGFRA</i>	4q12	Upregulated in CRC	[26]
72	<i>PECR</i>	2q35	Found LoF mutation in serrated polyposis families	[2]
73	<i>PIK3CA</i>	3q26.3	Cowden syndrome, frequently mutated in CRC	[4, 27]
74	<i>PMS2</i>	7p22.1	Candidate serrated polyposis gene	[23]
75	<i>POLD1</i>	19q13.3	Hereditary multiple adenomas / CRC	[28]
76	<i>POLD2</i>	7p13	Candidate for hereditary multiple adenomas / CRC	[28]
77	<i>POLD3</i>	11q14	Candidate for hereditary multiple adenomas / CRC	[28]
78	<i>POLD4</i>	11q13	Candidate for hereditary multiple adenomas / CRC	[28]
79	<i>POLE</i>	12q24.3	Hereditary multiple adenomas / CRC	[28]
80	<i>POLE2</i>	14q21	Candidate for hereditary multiple adenomas / CRC	[28]
81	<i>POLE3</i>	9q33	Candidate for hereditary multiple adenomas / CRC	[28]
82	<i>POLE4</i>	2p12	Candidate for hereditary multiple adenomas / CRC	[28]
83	<i>PPP2R1B</i>	11q23	MAPK pathway, candidate TSG, frequently mutated in CRC	[5]
84	<i>PQLC1</i>	18q23	Candidate serrated polyposis gene	[18]
85	<i>PTEN</i>	10q23.3	Target gene in MMR-deficient CRC	[1]
86	<i>PTPN13</i>	4q21	Found LoF mutation in serrated polyposis families	[2]
87	<i>PTPRJ</i>	11p11.2	Frequently mutated in colorectal adenomas / CRC	[8]

88	<i>PWP2</i>	21q22	Found LoF mutation in serrated polyposis families	[2]
89	<i>RASL10B</i>	17q12	Candidate serrated polyposis gene	[18]
90	<i>RGS19</i>	20q13	Found LoF mutation in serrated polyposis families	[2]
91	<i>RIZ</i>	1p36	Target gene in MMR-deficient CRC	[1]
92	<i>RNF43</i>	17q22	Play a role in serrated neoplasia pathway	[2]
93	<i>SEC16B</i>	1q25.2	Found LoF mutation in serrated polyposis families	[2]
94	<i>SEEL</i>	13q22.3	Found LoF mutation in serrated polyposis families	[2]
95	<i>SEC63</i>	6q21	Target gene in MMR-deficient CRC	[1]
96	<i>SEMG1</i>	20q13	Frequently overexpressed in <i>BRF</i> -mutant colon cancer	[11]
97	<i>SFRP1</i>	8p11.21	Candidate serrated polyposis gene	[19, 29]
98	<i>SLC22A2</i>	6q25.3	Found LoF mutation in serrated polyposis families	[2]
99	<i>SLC26A2</i>	5q32	Candidate serrated polyposis gene	[18]
100	<i>SLC27A6</i>	5q23.3	Found LoF mutation in serrated polyposis families	[2]
101	<i>SLC30A7</i>	1p21.2	Found LoF mutation in serrated polyposis families	[2]
102	<i>SLIT2</i>	4p15.31	Marker for CIMP	[23]
103	<i>SMAD2</i>	18q21.1	TGF-beta signaling pathway, frequently mutated in CRC	[4]
104	<i>SMAD4</i>	18q21.1	Juvenile polyposis syndrome (FJP)	[4]
105	<i>SSNA1</i>	9q34.3	Found LoF mutation in serrated polyposis families	[2]
106	<i>ST6GALNA C</i>	9q34.11	Found LoF mutation in serrated polyposis families	[2]
107	<i>STK11</i>	19p13.3	Target gene in MMR-deficient CRC	[1]
108	<i>SYTL1</i>	1p36.11	Found LoF mutation in serrated polyposis families	[2]
109	<i>TAS2R3</i>	7q34	Found LoF mutation in serrated polyposis families	[2]
110	<i>TBP</i>	6q27	Target gene in MMR-deficient CRC	[1]
111	<i>TCF4</i>	10q25.3	Target gene in MMR-deficient CRC	[1]
112	<i>TGFBR2</i>	3p22	Target gene in MMR-deficient CRC	[1]
113	<i>TP53</i>	17p13.1	Li-Fraumeni syndrome	[1]
114	<i>TRNP1</i>	1p36	Frequently overexpressed in <i>BRF</i> -mutant colon cancer	[11]
115	<i>USP45</i>	6q16.2	Found LoF mutation in serrated polyposis families	[2]
116	<i>WIF1</i>	12q14.3	Inhibitor of Wnt signaling pathway	[29]
117	<i>WRN</i>	8p12	Candidate serrated polyposis gene	[19]
118	<i>ZIC2</i>	13q32	Frequently overexpressed in <i>BRF</i> -mutant colon cancer	[11]
119	<i>ZIC5</i>	13q32	Frequently overexpressed in <i>BRF</i> -mutant colon cancer	[11]
120	<i>ZNF491</i>	19p13.2	Found LoF mutation in serrated polyposis families	[2]
121	<i>ZNF568</i>	19q13.12	Found LoF mutation in serrated polyposis families	[2]
122	<i>ZNF614</i>	19q13.41	Found LoF mutation in serrated polyposis families	[2]
123	<i>ZNF860</i>	3p23	Found LoF mutation in serrated polyposis families	[2]

CRC, colorectal cancer; HNPCC, hereditary nonpolyposis colorectal cancer; LoF, loss of function; MMR, mismatch repair

**Supplementary Table S2** Primers used for validating 25 variants by Sanger sequencing

No.	Gene	Chr	Position	Ref	Allele	Mut cDNA	Protein	Tu-ID	Forward primer (5'-3')	Reverse primer (5'-3')	size
1	ABI3BP <sup>#</sup>	3	100499047	T	A	c.2036A>T	p.K679M	71	GTTTCAGAGCTGAGCTGTCA	CTGGCAACTCTACCAAGTTTC	196
2	CALD1 <sup>#</sup>	7	134617870	G	A	c.332G>A	p.R111Q	69	AGTGAAGGGGATGATGAGG	GAGCGACAGACTTGTCATCTGT	136
3	CATSPERB <sup>#</sup>	14	92084032	G	T	c.2309C>A	p.P770H	71	TACATAACTGTCAGTATCATCAA	CCTTCAGAATAGATTCAGTTG	213
4	CCBP2 <sup>#</sup>	3	42906178	A	T	c.184A>T	p.S62C	72	GGTGTCTTTGGCAAAGTCT	GGCAGTGTACCAGAAACAG	177
5	CENPQ	6	49459907	G	T	c.726G>T	p.L242F	79	GCGATTCGTTGACAATTATTG	GGTTGACATGCTCTTCATCTG	224
6	CNTN5	11	99942566	G	T	c.1429G>T	p.A477S	70	GCTGGAATGTATCAGTGTGG	AATTAGAGCATGAAAAGAAGCAAG	135
7	COL8A1 <sup>#</sup>	3	99513118	G	A	c.373G>A	p.E125K	71	CATACCCCTTCTCTCTCTCTCT	CCTTTAATTCCAGGTATCCCAT	144
8	CPZ	4	8621320	G	T	c.1935G>T	p.R645S	69, 71	CCACATTGTCATTGCCCAA	CTTTGTGGGATGTCTGTGGC	415
9	CSPG4	15	75968509	G	T	c.6351C>A	p.D2117E	69	CCACAGCTCCAGAGTGAGAC	CTAGATGCTGGCGAGCTGG	240
10	DNAI1 <sup>#</sup>	9	34506717	G	A	c.1156G>A	p.V386I	71	AAGAACCCAGCTTCCCTGA	TTGGCTGAGCTGCAGAAGGA	170
11	FBLN5	14	92349339	G	T	c.821C>A	p.P274H	69	ACAGCCTTACCTTGGCAGCTT	TCTCTGAGTTCCTTGCCAACA	115
12	KIAA1033	12	105558425	G	T	c.3361G>T	p.E1121*	79	TTGGTATTTGCCATAATAAGTA	TAAACCACTCACTGACCTTC	177
13	KLHDC1	14	50201340	G	T	c.857G>T	p.C286F	78	ATTGTATCCAGAGACCTAATCT	GAAAGATATCCTTCTCAATGGC	242
14	NEURL1B	5	172096909	G	T	c.153G>T	p.R51R	80	AGGAGTTCGGAGGAGGCCTAAC	ATCGTGCGGGTGAAGCCGAA	330
15	NOL11	17	65716083	G	T	c.312+5G>T	SS	80	GTTGTACACGATAATAAGGTGAG	GAATGAAAACCTGATTAGGACCT	324
16	PPP3CB	10	75230956	G	T	c.681C>A	p.F227L	71	TCGGACCATAACAAGTCACAC	TTGGTATCGTTTTCTATGCAC	138
17	PROB1	5	138728291	G	T	c.2480C>A	p.P827H	78	CGCTCCCTGGGAGGGGCTTT	TAGGGCCAGCAGGGGTCCGAT	239
18	PRR23A	3	138725070	G	T	c.41C>A	p.P14H	73	TGGCGGGAGCTCCAGCACCA	CGCTCCCTACGTCCTCTGCTA	296
19	RAPH1	2	204305718	G	T	c.2195C>A	p.P732Q	71	GCTGAACCTGATGGATCTTCAG	CAATGGAGTTGTTCCACCAC	146
20	RGS13	1	192613504	G	T	c.40G>T	p.D14Y	73	CCCAGTGACTGTATTCCATTAAC	CATATGACTGCTCTTCTGATGAA	365
21	RIF1	2	152321774	G	T	c.5740G>T	p.A1914S	78, 79	CCCCAAAATGGAAGTCTGAG	GGTCTCTCTTGTCCATGAAAG	140
22	SLC27A3	1	153748613	G	T	c.781G>T	p.G261C	79	GTTTCTGTGGCTCTGGTTCCG	GTTCCGGAGCTCCAGCCTTA	151
23	TRIM13	13	50587208	G	T	c.1132G>T	p.G378W	69	TGGTCTACCATGTTCTAG	ACCAAATCTGAATTACACTCT	308
24	UBE2CBP	6	83732195	G	T	c.823C>A	p.Q275K	80	GAGACCTTGGATTCTAGGCT	CAGGTCTGGTTTGTCCAGAG	162

25	VGLL2#	6	117589395	C	A	c.132C>A	p.S44R	70	ATCAGTCTGAACCGAATTTGC	TTATACTGGCTGGGGTTTGG	176
----	--------	---	-----------	---	---	----------	--------	----	-----------------------	----------------------	-----

# mutations were validated

## References

1. Grady WM, Carethers JM: **Genomic and epigenetic instability in colorectal cancer pathogenesis.** *Gastroenterology* 2008, **135**(4):1079-1099.
2. Yan HH, Lai JC, Ho SL, Leung WK, Law WL, Lee JF, Chan AK, Tsui WY, Chan AS, Lee BC *et al*: **RNF43 germline and somatic mutation in serrated neoplasia pathway and its association with BRAF mutation.** *Gut* 2016.
3. Groden J, Thliveris A, Samowitz W, Carlson M, Gelbert L, Albertsen H, Joslyn G, Stevens J, Spirio L, Robertson M *et al*: **Identification and characterization of the familial adenomatous polyposis coli gene.** *Cell* 1991, **66**(3):589-600.
4. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N *et al*: **The consensus coding sequences of human breast and colorectal cancers.** *Science* 2006, **314**(5797):268-274.
5. Suraweera N, Robinson J, Volikos E, Guenther T, Talbot I, Tomlinson I, Silver A: **Mutations within Wnt pathway genes in sporadic colorectal cancers and cell lines.** *Int J Cancer* 2006, **119**(8):1837-1842.
6. O'Brien MJ, Yang S, Mack C, Xu H, Huang CS, Mulcahy E, Amoroso M, Farrar FA: **Comparison of microsatellite instability, CpG island methylation phenotype, BRAF and KRAS status in serrated polyps and traditional adenomas indicates separate pathways to distinct colorectal carcinoma end points.** *Am J Surg Pathol* 2006, **30**(12):1491-1501.
7. de Voer RM, Geurts van Kessel A, Weren RD, Ligtenberg MJ, Smeets D, Fu L, Vreede L, Kamping EJ, Verwiel ET, Hahn MM *et al*: **Germline mutations in the spindle assembly checkpoint genes BUB1 and BUB3 are risk factors for colorectal cancer.** *Gastroenterology* 2013, **145**(3):544-547.
8. Venkatchalam R, Verwiel ET, Kamping EJ, Hoenselaar E, Gorgens H, Schackert HK, van Krieken JH, Ligtenberg MJ, Hoogerbrugge N, van Kessel AG *et al*: **Identification of candidate predisposing copy number variants in familial and early-onset colorectal cancer patients.** *Int J Cancer* 2011, **129**(7):1635-1642.
9. Suchy J, Cybulski C, Wokolorczyk D, Oszurek O, Gorski B, Debniak T, Jakubowska A, Gronwald J, Huzarski T, Byrski T *et al*: **CHEK2 mutations and HNPCC-related colorectal cancer.** *Int J Cancer* 2010, **126**(12):3005-3009.
10. Cybulski C, Wokolorczyk D, Kladny J, Kurzawski G, Suchy J, Grabowska E, Gronwald J, Huzarski T, Byrski T, Gorski B *et al*: **Germline CHEK2 mutations and colorectal cancer risk: different effects of a missense and truncating mutations?** *Eur J Hum Genet* 2007, **15**(2):237-241.
11. Kanth P, Bronner MP, Boucher KM, Burt RW, Neklason DW, Hagedorn CH, Delker DA: **Gene Signature in Sessile Serrated Polyps Identifies Colon Cancer Subtype.** *Cancer Prev Res (Phila)* 2016, **9**(6):456-465.
12. Pendas-Franco N, Aguilera O, Pereira F, Gonzalez-Sancho JM, Munoz A: **Vitamin D and Wnt/beta-catenin pathway in colon cancer: role and regulation of DICKKOPF genes.** *Anticancer Res* 2008, **28**(5A):2613-2623.
13. Pastorino U, Sozzi G, Miozzo M, Tagliabue E, Pilotti S, Pierotti MA: **Genetic changes in lung cancer.** *J Cell Biochem Suppl* 1993, **17F**:237-248.
14. Kim MJ, Lee EJ, Suh JP, Chun SM, Jang SJ, Kim DS, Lee DH, Lee SH, Youk EG: **Traditional serrated adenoma of the colorectum: clinicopathologic implications and endoscopic findings of the precursor lesions.** *Am J Clin Pathol* 2013, **140**(6):898-911.
15. Kuiper RP, Vissers LE, Venkatchalam R, Bodmer D, Hoenselaar E, Goossens M, Haufe A, Kamping E, Niessen RC, Hogervorst FB *et al*: **Recurrence and variability of germline EPCAM deletions in Lynch syndrome.** *Hum Mutat* 2011, **32**(4):407-414.
16. Sanz-Pamplona R, Lopez-Doriga A, Pare-Brunet L, Lazaro K, Bellido F, Alonso MH, Ausso S, Guino E, Beltran S, Castro-Giner F *et al*: **Exome Sequencing Reveals AMER1 as a Frequently Mutated Gene in Colorectal Cancer.** *Clin Cancer Res* 2015, **21**(20):4709-4718.
17. Major MB, Camp ND, Berndt JD, Yi X, Goldenberg SJ, Hubbert C, Biechele TL, Gingras AC, Zheng N, Maccoss MJ *et al*: **Wilms tumor suppressor WTX negatively regulates WNT/beta-catenin signaling.** *Science* 2007, **316**(5827):1043-1046.

18. Inoue M, Takahashi S, Soeda H, Shimodaira H, Watanabe M, Miura K, Sasaki I, Kato S, Ishioka C: **Gene-expression profiles correlate with the efficacy of anti-EGFR therapy and chemotherapy for colorectal cancer.** *Int J Clin Oncol* 2015, **20**(6):1147-1155.
19. Esteller M: **Epigenetics in cancer.** *N Engl J Med* 2008, **358**(11):1148-1159.
20. Kaji E, Uraoka T, Kato J, Hiraoka S, Suzuki H, Akita M, Saito S, Tanaka T, Ohara N, Yamamoto K: **Externalization of saw-tooth architecture in small serrated polyps implies the presence of methylation of IGFBP7.** *Dig Dis Sci* 2012, **57**(5):1261-1270.
21. Leary RJ, Lin JC, Cummins J, Boca S, Wood LD, Parsons DW, Jones S, Sjoblom T, Park BH, Parsons R *et al*: **Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers.** *Proc Natl Acad Sci U S A* 2008, **105**(42):16224-16229.
22. Lee JW, Soung YH, Kim SY, Nam SW, Park WS, Lee JY, Yoo NJ, Lee SH: **Kinase domain mutation of MAP2K4 is rare in gastric, colorectal and lung carcinomas.** *Pathology* 2006, **38**(3):263-264.
23. Beggs AD, Jones A, Shepherd N, Arnaout A, Finlayson C, Abulafi AM, Morton DG, Matthews GM, Hodgson SV, Tomlinson IP: **Loss of expression and promoter methylation of SLIT2 are associated with sessile serrated adenoma formation.** *PLoS Genet* 2013, **9**(5):e1003488.
24. Al-Tassan N, Chmiel NH, Maynard J, Fleming N, Livingston AL, Williams GT, Hodges AK, Davies DR, David SS, Sampson JR *et al*: **Inherited variants of MYH associated with somatic G:C-->T:A mutations in colorectal tumors.** *Nat Genet* 2002, **30**(2):227-232.
25. Irahara N, Baba Y, Nosho K, Shima K, Yan L, Dias-Santagata D, Iafrate AJ, Fuchs CS, Haigis KM, Ogino S: **NRAS mutations are rare in colorectal cancer.** *Diagn Mol Pathol* 2010, **19**(3):157-163.
26. Dai YC, Zhu XS, Nan QZ, Chen ZX, Xie JP, Fu YK, Lin YY, Lian QN, Sang QF, Zhan XJ: **Identification of differential gene expressions in colorectal cancer and polyp by cDNA microarray.** *World J Gastroenterol* 2012, **18**(6):570-575.
27. Nosho K, Kawasaki T, Ohnishi M, Suemoto Y, Kirkner GJ, Zepf D, Yan L, Longtine JA, Fuchs CS, Ogino S: **PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations.** *Neoplasia* 2008, **10**(6):534-541.
28. Palles C, Cazier JB, Howarth KM, Domingo E, Jones AM, Broderick P, Kemp Z, Spain SL, Guarino E, Salguero I *et al*: **Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas.** *Nat Genet* 2013, **45**(2):136-144.
29. Huang S, Zhong X, Gao J, Song R, Wu H, Zi S, Yang S, Du P, Cui L, Yang C *et al*: **Coexpression of SFRP1 and WIF1 as a prognostic predictor of favorable outcomes in patients with colorectal carcinoma.** *Biomed Res Int* 2014, **2014**:256723.